19-Alkoxy 17-Substituted Steroids for GABA Anesthetic Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for the synthesis and understanding of new neuroactive steroids with utility as anesthetics and in the treatment of disorders related to GABA function, as existing compounds like alphaxalone and Δ16-alphaxalone have varying anesthetic activities due to structural differences, particularly at the C-17 position of the D-ring.

Innovation Solution

Development of 19-alkoxy-17-substituted steroids, such as 19-methoxy-17-substituted steroids, with specific tetracyclic structures that enhance GABA A receptor activity, offering potential as anesthetics and treatments for disorders like insomnia, mood disorders, anxiety, and ethanol withdrawal.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing neuroactive steroids like alphaxalone are used, then anesthetic activity is achieved, but structural limitations prevent optimization of GABA A receptor activity

Engineering Contradiction:

Improveanesthetic activityVSAvoidstructural variability at C-17 position

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent systematically varies substituents at the C-17 position of the steroid D-ring, testing different functional groups (hydroxyl, methoxyl, ethoxyl, isopropoxyl, cyclopropylmethyl, etc.) to optimize GABA A receptor activity and anesthetic properties while maintaining the core neuroactive steroid structure

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention modifies specific local regions of the steroid molecule (C-17 position substitutions) while preserving the overall tetracyclic steroid framework and other critical structural features (19-alkoxy group, 3-hydroxyl group) that are essential for neuroactive activity

Inventive Principle:

Principle #3Local quality

2Reliability

If conventional anesthetics are administered, then anesthesia is achieved, but bacterial contamination risk and solubility issues arise

Engineering Contradiction:

Improveanesthetic efficacyVSAvoidbacterial contamination risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces sterically hindered alcohol substituents at C-17 that reduce bacterial adhesion and biofilm formation, thereby lowering contamination risk while maintaining anesthetic efficacy through optimized GABA A receptor potentiation

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The 19-alkoxy-17-substituted steroids provide effective anesthetic properties and therapeutic benefits for GABA-related disorders, with advantages including lower bacterial contamination risk and improved solubility, making them suitable for continuous infusion sedation during procedures like colonoscopy.

Implementation Method 1

it is now widely accepted that the intravenous anesthetic alphaxalone (Compound A, below) causes general anesthesia in humans because it allosterically increases chloride currents mediated by GABA acting at GABA A receptors in the brain

Methodology Applied

Scientific EffectAllosteric modulation:

Implementation Method 2

activation of the receptor induces increased inward chloride ion flux, resulting in membranehyperpolarization and neuronal inhibition

Methodology Applied

Scientific EffectIon flux:

Data Source

PatentEP4086270B1Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment

Publication Date: 2026.03.04 SAGE THERAPEUTICS LLC

AI summary

The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.